je.st
news
Juno is just one part of Celgene's master plan
2015-07-17 23:53:28| Biotech - Topix.net
Seattle biotech Juno Therapeutics' new partner in the immunotherapy game isn't just interested in treatments for cancer. New Jersey biopharmaceutical company Celgene Corp. on Tuesday announced it will acquire San Diego-based autoimmune disease treatment company Receptos for $7.2 billion, about $232 per share .
Tags: part
plan
master
juno
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||